Table 1.

Clinical and demographic characteristics

Variable	LN patients with two or more renal biopsies (n = 220)
Female, n (%)	199 (90)
Age at first biopsy, median (range), years	28 (9–60)
Race/ethnicity, n (%)
Black/African American	118 (54)
White	59 (27)
Asian	25 (11)
Other	18 (8)
Time between first and second biopsy, mean (range), years	3.9 (0.3–28)
Treatment after first biopsy (n = 63), n (%)
HCQ	51 (81)
Mycophenolate	31 (49)
AZA	12 (19)
CYC	4 (6)
Prednisone	52 (82)
ACE inhibitors or ARBs	24 (38)
Vitamin D (n = 21)	16 (76)
Treatment at the time of second biopsy (n = 64), n (%)
HCQ	57 (89)
Mycophenolate	38 (59)
AZA	14 (22)
CYC	1 (1.6)
Prednisone (n = 54)	40 (63)
ACE inhibitors or ARBs	37 (58)
Vitamin D (n = 39)	33 (52)
Tacrolimus	1 (1.6)

All LN patients in the Hopkins Lupus Cohort with two or more renal biopsies were included (n = 220, 542 biopsies).